High-bioavailability astaxanthin microcapsule and preparation method thereof
By mixing astaxanthin with polysaccharides, cellulose derivatives and surfactants and preparing microcapsules, the water solubility and stability of astaxanthin are solved, and its bioavailability and stability are improved, achieving better Medicinal effect.
Patent Information
- Application Number
- CN202411067834.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-06
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Astaxanthin has poor water solubility, low bioavailability and poor stability, which leads to oxidative degradation in processing and storage, limiting its application in functional health products.
Microcapsules are prepared by solvent method or melting method using mixtures of astaxanthin, polysaccharides, cellulose derivatives and surfactants, so that astaxanthin remains amorphous, colloidal dispersion or molecular dispersion, and improves its dissolution rate and Bioavailability and enhance stability through materials such as octenyl succinate starch ester and hydroxypropyl methylcellulose.
It improves the bioavailability and stability of astaxanthin, inhibits recrystallization, enhances its dissolution in the release medium, and ensures the efficacy of the medicine.
Smart Images

Figure CN118902137A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of functional foods, and in particular to a high-bioavailability astaxanthin microcapsule and a preparation method thereof. Background Art
[0002] Astaxanthin (ASTX) is a xanthophyll carotenoid with an orange-red color. It is a natural pigment that is widely found in organisms, especially in aquatic animals such as shrimp, crab, and fish. It is also found in bird feathers, microorganisms, and certain algae. As a potent oxidant, it has a strong antioxidant capacity and can effectively inhibit free radical-induced lipid peroxidation. At the same time, it also has a variety of physiological effects, such as preventing cancer, enhancing immunity, scavenging free radicals in the body, and reducing the incidence of neurological and cardiovascular diseases. In addition, it has a good therapeutic effect on skin cancer caused by ultraviolet rays, has a preventive effect on eye diseases caused by diabetes, and plays an indispensable role in various physiological processes of the human body. Therefore, in recent years, its potential applications in functional health products, medicines, cosmetics, and food additives have attracted more and more attention from consumers.
[0003] However, astaxanthin has poor water solubility, limited oral bioaccessibility, and poor bioavailability, which poses a challenge to incorporating large amounts of astaxanthin into industrial products, thus limiting its application. In addition, due to the abundance of unsaturated conjugated double bonds in its molecular structure, its chemical stability is relatively insufficient, especially during processing and storage, and it is susceptible to oxidative degradation by high temperature, strong light, and strong acids and bases, ultimately leading to reduced biological activity. Therefore, various drug delivery systems, including liposomes, nanoparticles, emulsion gels, and electrospun nanofibers have been used to deliver astaxanthin to improve its solubility, stability, bioaccessibility, and bioavailability.
[0004] In recent years, microencapsulation technology has become an effective way to solve the problem of dissolution rate and oral bioavailability of poorly water-soluble bioactive substances. The bioactive substance-excipient interaction effectively inhibits the aggregation of API molecules, thereby significantly improving their solubility, promoting their long-term supersaturation, and ultimately promoting the absorption of APIs. The basic mechanism of action of microencapsulation involves the conversion of highly crystalline drug small molecules into amorphous states, a process that reduces the energy barrier for lattice destruction and promotes the dissolution of drugs. However, amorphous drugs have the characteristics of high energy and may still be unstable under high energy, leading to recrystallization and reduction of drug concentrations in vivo and in vitro, ultimately resulting in poor bioavailability. Summary of the invention
[0005] The purpose of the present invention is to provide a high-bioavailability astaxanthin microcapsule and a preparation method thereof, so as to solve the problems of poor water solubility, low bioavailability and poor stability of existing astaxanthin drugs leading to in vitro and in vivo recrystallization of astaxanthin.
[0006] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0007] The present invention provides a method for preparing astaxanthin microcapsules with high bioavailability, comprising the following steps:
[0008] Astaxanthin, polysaccharide, cellulose derivative and surfactant are mixed to obtain a mixture, and astaxanthin microcapsules are obtained through a solvent method or a melting method.
[0009] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the polysaccharide is sodium alginate, chitosan, β-cyclodextrin, inulin, maltodextrin or octenyl succinate starch.
[0010] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the cellulose derivative is hydroxypropyl methylcellulose, polyvinylpolypyrrolidone, copovidone or polyethylene glycol.
[0011] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the surfactant is sorbitan fatty acid ester, sodium lauryl sulfate, vitamin E polyethylene glycol succinate, polyoxyethylene castor oil or polyoxyethylene (20) sorbitan monooleate.
[0012] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the mass ratio of astaxanthin, polysaccharide, cellulose derivative and surfactant is 10.52:50-80:20-50:100.
[0013] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the solvent method comprises:
[0014] The mixture is mixed with an organic solvent, dispersed and dried to obtain astaxanthin microcapsules.
[0015] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the volume ratio of the mixture to the organic solvent is 1000-1055 mg: 10-15 mL;
[0016] The organic solvent is ethanol, acetone or dichloromethane;
[0017] The drying temperature is 40-60° C., and the drying time is 4-6 hours.
[0018] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the melting method comprises:
[0019] The mixture is melted and cooled to obtain astaxanthin microcapsules.
[0020] Preferably, in the above method for preparing astaxanthin microcapsules with high bioavailability, the melting temperature is >240° C., and the melting time is 15 to 20 min.
[0021] The invention also provides astaxanthin microcapsules prepared by a method for preparing astaxanthin microcapsules with high bioavailability.
[0022] It can be seen from the above technical solution that compared with the prior art, the present invention has the following beneficial effects:
[0023] (1) The present invention embeds astaxanthin in microcapsules, so that astaxanthin remains in a highly dispersed state and exists in an amorphous state, a colloidal dispersion state or a molecular dispersion state, with a large dispersion degree. The dissolution rate of astaxanthin is accelerated, which can promote the absorption of astaxanthin and improve its bioavailability.
[0024] (2) The octenyl succinate starch ester used in the present invention has a highly branched structure and is an amphiphilic polymer with strong emulsification ability and solubility, high stability, and is widely used in the field of functional foods.
[0025] (3) The cellulose derivative hydroxypropyl methylcellulose used in the present invention has an excellent crystallization inhibiting effect, which solves the problem of crystallization after dissolution when preparing microcapsules using other carrier materials. In addition, the prepared microcapsules have relatively low hygroscopicity and high stability.
[0026] (4) The surfactant sorbitan fatty acid ester used in the present invention has an excellent solubilizing effect, which makes the prepared astaxanthin microcapsules have better solubility, greatly increases the dissolution amount of astaxanthin in the release medium, and further improves its bioavailability, ensuring the efficacy. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required to be used in the description of the embodiments or the prior art are briefly introduced below.
[0028] Figure 1 is the equilibrium solubility of astaxanthin in different solutions in Example 1;
[0029] Figure 2 The figure is a graph of the recrystallization rate of astaxanthin in solutions containing different polysaccharides; (A) is the concentration change, and (B) is the particle size change;
[0030] Figure 3The equilibrium solubility of astaxanthin in mixed solutions containing octenyl succinate starch ester / surfactant at different ratios and mixed solutions containing chitosan / surfactant at different ratios in Examples 3 to 8, and the recrystallization rate of astaxanthin in mixed solutions containing octenyl succinate starch ester / Span 20 at different ratios and mixed solutions containing chitosan / Span 20 at different ratios; wherein, (A) is the equilibrium solubility of astaxanthin in mixed solutions containing octenyl succinate starch ester / surfactant at different ratios in Examples 3 and 4, (B) is the equilibrium solubility of astaxanthin in mixed solutions containing chitosan / surfactant at different ratios in Examples 5 and 6, (C) is the recrystallization rate of astaxanthin in mixed solutions containing octenyl succinate starch ester / Span 20 at different ratios in Example 7, and (D) is the recrystallization rate of astaxanthin in mixed solutions containing chitosan / Span 20 at different ratios in Example 8;
[0031] Figure 4 is the recrystallization rate of astaxanthin in solutions containing different cellulose derivatives in Example 9; wherein (A) is the concentration change, and (B) is the particle size change;
[0032] Figure 5 The equilibrium solubility of astaxanthin in the combined solutions containing HPMC E5 / surfactant at different ratios in Examples 10 to 12 and the recrystallization rate of astaxanthin in the mixed solutions containing HPMC E5 / Span 20 at different ratios; wherein (A) is the equilibrium solubility of astaxanthin in the combined solutions containing HPMC E5 / surfactant at different ratios in Examples 10 and 11, and (B) is the recrystallization rate of astaxanthin in the mixed solutions containing HPMC E5 / Span 20 at different ratios in Example 12;
[0033] Figure 6 is the recrystallization rate of astaxanthin in Example 13 in mixed solutions containing different ratios of OSA-starch / HPMC E5 / Span20;
[0034] Figure 7 is the dissolution curve of astaxanthin microcapsules in PBS solution in Example 14;
[0035] Figure 8 The DSC spectra of astaxanthin raw powder and astaxanthin microcapsules in Example 14 are shown. DETAILED DESCRIPTION
[0036] The present invention provides a method for preparing astaxanthin microcapsules with high bioavailability, comprising the following steps:
[0037] Astaxanthin, polysaccharide, cellulose derivative and surfactant are mixed to obtain a mixture, and astaxanthin microcapsules are obtained through a solvent method or a melting method.
[0038] In the present invention, the polysaccharide is preferably sodium alginate, chitosan, β-cyclodextrin, inulin, maltodextrin or octenyl succinate starch, more preferably chitosan or octenyl succinate starch, and more preferably octenyl succinate starch.
[0039] In the present invention, the cellulose derivative is preferably hydroxypropyl methylcellulose, polyvinyl polypyrrolidone, copovidone or polyethylene glycol, further preferably hydroxypropyl methylcellulose or polyvinyl polypyrrolidone, more preferably hydroxypropyl methylcellulose;
[0040] The hydroxypropyl methylcellulose is preferably hydroxypropyl methylcellulose E5 type.
[0041] In the present invention, the surfactant is preferably sorbitan fatty acid ester, sodium lauryl sulfate, vitamin E polyethylene glycol succinate, polyoxyethylene castor oil or polyoxyethylene (20) sorbitan monooleate, further preferably sorbitan fatty acid ester or polyoxyethylene (20) sorbitan monooleate, more preferably sorbitan fatty acid ester.
[0042] In the present invention, the mass ratio of astaxanthin, polysaccharide, cellulose derivative and surfactant is preferably 10.52:50-80:20-50:100, more preferably 10.52:50-60:40-50:100, and more preferably 10.52:50:50:100.
[0043] In the present invention, the process of the solvent method is:
[0044] The mixture is mixed with an organic solvent, dispersed and dried to obtain astaxanthin microcapsules.
[0045] In the present invention, the mass ratio of the mixture to the volume ratio of the organic solvent is preferably 1000-1055 mg:10-15 mL, more preferably 1020-1053 mg:12-15 mL, and even more preferably 1052.6 mg:15 mL.
[0046] In the present invention, the organic solvent is preferably ethanol, acetone or dichloromethane, more preferably ethanol or acetone, and more preferably ethanol.
[0047] In the present invention, the dispersion method is preferably stirring or ultrasound;
[0048] The dispersion temperature is preferably 23-27°C, more preferably 24-26°C, and more preferably 25°C;
[0049] The dispersion time is preferably 5 to 15 minutes, more preferably 12 to 15 minutes, and more preferably 15 minutes.
[0050] The power of the ultrasound is preferably 200-300W, more preferably 220-280W, and more preferably 230-250W.
[0051] In the present invention, the drying temperature is preferably 40-60°C, more preferably 42-55°C, and more preferably 45-50°C; the drying time is preferably 4-6h, more preferably 4.5-5.5h, and more preferably 5h.
[0052] In the present invention, the process of the melting method is:
[0053] The mixture is melted and cooled to obtain astaxanthin microcapsules.
[0054] In the present invention, the step before melting also includes: grinding.
[0055] In the present invention, the melting temperature is preferably >240°C, more preferably 245-300°C, and more preferably 250°C; the melting time is preferably 15-20 min, more preferably 16-19 min, and more preferably 17-18 min.
[0056] The invention also provides astaxanthin microcapsules prepared by a method for preparing astaxanthin microcapsules with high bioavailability.
[0057] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0058] In the following examples, the astaxanthin raw powder was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0059] Example 1
[0060] Prepare 50 mL of sodium alginate solution, maltodextrin solution, chitosan solution, β-cyclodextrin solution, inulin solution, and octenyl succinate starch solution at 0.5 mg / mL and pH 7.4, respectively, add 5 mg of astaxanthin powder to each of the above solutions, stir at 37°C and 150 rpm for 24 h, then take samples, and use U-3700 UV-visible spectrophotometer to detect the astaxanthin content at 480 nm;
[0061] Prepare 50 mL of 10 mM phosphate buffer solution (PBS solution) with a pH of 7.4, add 5 mg of astaxanthin raw powder, stir at 37°C and 150 rpm for 24 hours, then take a sample, and use a U-3700 UV-visible spectrophotometer to detect the astaxanthin content at 480 nm.
[0062] Figure 1 is the equilibrium solubility of astaxanthin in different solutions in Example 1. Figure 1 It can be seen that the solubility of astaxanthin raw powder in PBS solution (10mM, pH=7.4) is only 0.02μg / mL; astaxanthin shows a certain solubilization effect in sodium alginate solution, maltodextrin solution, chitosan solution, β-cyclodextrin solution, inulin solution and octenyl succinate starch solution, but the overall solubilization effect is limited, and the solubility of astaxanthin is not much different among polysaccharides.
[0063] Example 2
[0064] Dissolve astaxanthin raw powder in tetrahydrofuran to obtain 5 mg / mL astaxanthin organic solution;
[0065] Prepare 50 mL each of 0.5 mg / mL sodium alginate solution, maltodextrin solution, chitosan solution, β-cyclodextrin solution, inulin solution and octenyl succinate starch solution at pH 7.4; add 250 μL of astaxanthin organic solution to the above solutions respectively, stir at 37°C and 150 rpm, take samples at 5, 15, 30, 60, 90 and 120 min, use U-3700 UV-Vis spectrophotometer to detect the astaxanthin content at 480 nm, and use Nano ZSP instrument to measure the particle size of the samples.
[0066] The recrystallization rate of astaxanthin in Example 2 in solutions containing different polysaccharides is as follows: Figure 2 As shown. Figure 2 It can be seen that different polysaccharides have different abilities to maintain astaxanthin supersaturation; as time goes by, the concentration of astaxanthin gradually decreases and the particle size of the solution gradually increases. Chitosan and octenyl succinate starch have the best anti-crystallization effect, which can maintain the solution particle size below 2000nm for a long time, and there is no significant difference in the anti-crystallization effect of the two.
[0067] Example 3
[0068] Prepare a 1 mg / mL solution of starch octenyl succinate at a pH of 7.4;
[0069] Prepare a 1 mg / mL, pH 7.4 solution of sorbitan fatty acid ester (Span 20);
[0070] The octenyl succinate starch ester solution and the sorbitan fatty acid ester (Span 20) solution were mixed in a volume ratio of 9:1, 8:2, 7:3, 6:4, and 5:5 to obtain 50 mL of each mixed solution, and then 5 mg of astaxanthin raw powder was added respectively. The samples were stirred at 37°C and 150 rpm for 24 hours, and the astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0071] Example 4
[0072] The same as in Example 3, except that sorbitan fatty acid ester (Span 20) is replaced by sodium dodecyl sulfate (SDS), polyoxyethylene (20) sorbitan monooleate (Tween 80), vitamin E polyethylene glycol succinate (TPGS), and polyoxyethylene castor oil (Cremophor EL), respectively.
[0073] Example 5
[0074] Prepare a chitosan solution of 1 mg / mL and pH 7.4;
[0075] Prepare a 1 mg / mL, pH 7.4 solution of sorbitan fatty acid ester (Span 20);
[0076] The chitosan solution and the sorbitan fatty acid ester (Span 20) solution were mixed in a volume ratio of 9:1, 8:2, 7:3, 6:4, and 5:5 to obtain 50 mL of each mixed solution. Then, 5 mg of astaxanthin raw powder was added to each solution. The mixture was stirred at 37°C and 150 rpm for 24 h, and samples were taken. The astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0077] Example 6
[0078] The same as in Example 5, except that sorbitan fatty acid ester (Span 20) is replaced by sodium dodecyl sulfate (SDS), polyoxyethylene (20) sorbitan monooleate (Tween 80), vitamin E polyethylene glycol succinate (TPGS), and polyoxyethylene castor oil (Cremophor EL), respectively.
[0079] Example 7
[0080] Dissolve astaxanthin raw powder in tetrahydrofuran to obtain 5 mg / mL astaxanthin organic solution;
[0081] Prepare a 1 mg / mL solution of starch octenyl succinate at a pH of 7.4;
[0082] Prepare a 1 mg / mL, pH 7.4 solution of sorbitan fatty acid ester (Span 20);
[0083] The octenyl succinate starch ester solution and the sorbitan fatty acid ester (Span 20) solution were mixed in a volume ratio of 9:1, 8:2, 7:3, 6:4, and 5:5 to obtain 50 mL of each mixed solution. 250 μL of astaxanthin organic solution was added to the mixed solution, and the mixture was stirred at 37°C and 150 rpm. Samples were taken at 5, 15, 30, 60, 90, and 120 min, and the astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0084] Example 8
[0085] The same as Example 7, except that octenyl succinate starch is replaced by chitosan.
[0086] The equilibrium solubility of astaxanthin in mixed solutions containing different ratios of octenyl succinate starch ester / surfactant and chitosan / surfactant in Examples 3 to 8 and the recrystallization rate (concentration change) of astaxanthin in mixed solutions containing different ratios of octenyl succinate starch ester / Span 20 and chitosan / Span 20 are shown in Figure 3. Figure 3 As shown. Figure 3 It can be seen that astaxanthin shows a certain solubilization effect in both the mixed solution containing octenyl succinate starch ester / surfactant and the mixed solution containing chitosan / surfactant. When octenyl succinate starch ester and chitosan are used in combination with surfactant Span 20, the solubilization effect of astaxanthin is the best; and when the mass ratio of octenyl succinate starch ester to Span 20 is 5:5, and the mass ratio of chitosan to Span 20 is 5:5, the solubilization effect of astaxanthin is the best and the crystal inhibition effect is the best.
[0087] Example 9
[0088] Dissolve astaxanthin raw powder in tetrahydrofuran to obtain 5 mg / mL astaxanthin organic solution;
[0089] Prepare 50 mL of 0.5 mg / mL, pH=7.4 hydroxypropyl methylcellulose (HPMC E5) solution, polyvinyl polypyrrolidone (PVP K30) solution, copovidone (PVPVA64) solution, and polyethylene glycol (PEG 6000) solution respectively, add 250 μL of astaxanthin organic solution to each solution, stir at 37°C and 150 rpm, take samples at 5, 15, 30, 60, 90 and 120 min, use U-3700 UV-visible spectrophotometer to detect the astaxanthin content at 480 nm, and use Nano ZSP instrument to determine the particle size of the samples.
[0090] The recrystallization rate of astaxanthin in the solutions containing different cellulose derivatives in Example 9 is as follows: Figure 4 As shown. Figure 4 It can be seen that different cellulose derivatives have different abilities to maintain astaxanthin supersaturation; as time goes by, the concentration of astaxanthin gradually decreases and the particle size of the solution gradually increases. HPMC E5 has the best crystal inhibition effect and can maintain the particle size of the solution at around 1500nm for a long time.
[0091] Example 10
[0092] Prepare a 1 mg / mL HPMC E5 solution at pH 7.4;
[0093] Prepare a 1 mg / mL, pH 7.4 solution of sorbitan fatty acid ester (Span 20);
[0094] HPMC E5 solution and sorbitan fatty acid ester (Span 20) solution were mixed at a volume ratio of 9:1, 8:2, 7:3, 6:4, and 5:5 to obtain 50 mL of each mixed solution, and then 5 mg of astaxanthin raw powder was added. After stirring at 37°C and 150 rpm for 24 hours, samples were taken and the astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0095] Embodiment 11
[0096] The same as in Example 10, except that sorbitan fatty acid ester (Span 20) is replaced by sodium dodecyl sulfate (SDS), polyoxyethylene (20) sorbitan monooleate (Tween 80), vitamin E polyethylene glycol succinate (TPGS), and polyoxyethylene castor oil (Cremophor EL), respectively.
[0097] Example 12
[0098] Dissolve astaxanthin raw powder in tetrahydrofuran to obtain 5 mg / mL astaxanthin organic solution;
[0099] Prepare a 1 mg / mL HPMC E5 solution at pH 7.4;
[0100] Prepare a 1 mg / mL, pH 7.4 solution of sorbitan fatty acid ester (Span 20);
[0101] The HPMC E5 solution and the sorbitan fatty acid ester (Span 20) solution were mixed in a volume ratio of 9:1, 8:2, 7:3, 6:4, and 5:5 to obtain 50 mL of each mixed solution. 250 μL of astaxanthin organic solution was added to the mixed solution, and the mixture was stirred at 37°C and 150 rpm. Samples were taken at 5, 15, 30, 60, 90, and 120 min, and the astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0102] The equilibrium solubility of astaxanthin in the combined solutions containing different ratios of HPMC E5 / surfactant and the recrystallization rate of astaxanthin in the mixed solutions containing different ratios of HPMC E5 / Span 20 in Examples 10 to 12 are as follows: Figure 5 As shown. Figure 5 It can be seen that astaxanthin shows a certain solubilization effect in the HPMC E5 / surfactant solution prepared above. When HPMC E5 is used in combination with surfactant Span 20, the solubilization effect of astaxanthin is the best; and when the mass ratio of HPMC E5 to Span 20 is 8:2 or 5:5, the solubilization effect of astaxanthin is the best; when the mass ratio is 6:4 or 5:5, the anti-crystal effect of astaxanthin is significant.
[0103] Embodiment 13
[0104] Dissolve astaxanthin raw powder in tetrahydrofuran to obtain 5 mg / mL astaxanthin organic solution;
[0105] 50 mL of solutions (pH = 7.4) were prepared according to the mass ratios of octenyl succinate starch ester (OSA-starch), HPMC E5 and Span 20 of 4:1:5, 3:1:4, 2:1:3 and 1:1:2, and the total concentration of octenyl succinate starch ester, HPMC E5 and Span 20 in each solution was 0.5 mg / mL; 250 μL of astaxanthin organic solution was added to the solutions, the solutions were stirred at 37°C and 150 rpm, samples were taken at 5, 15, 30, 60, 90 and 120 min, and the astaxanthin content was detected at 480 nm using a U-3700 UV-Vis spectrophotometer.
[0106] The recrystallization rate of astaxanthin in Example 13 in the mixed solution containing different ratios of OSA-starch / HPMC E5 / Span 20 is as follows: Figure 6 As shown. Figure 6 It can be seen that astaxanthin exhibits a certain anti-crystal effect in the prepared octenyl succinate starch ester / HPMC E5 / Span 20 solution. The anti-crystal effect of astaxanthin at different octenyl succinate starch ester / HPMC E5 / Span 20 mass ratios is not much different, but the overall effect is more significant than that of the octenyl succinate starch ester / Span 20 binary system or HPMCE5 / Span 20 binary system. It can be seen that the combination of polysaccharide octenyl succinate starch ester, hydroxypropyl methylcellulose, and Span 20 enhances the anti-crystal effect of the ternary system on astaxanthin.
[0107] Embodiment 14
[0108] Astaxanthin, octenyl succinate starch, HPMC E5 and Span 20 were mixed according to the proportions in Table 1, anhydrous ethanol was added, and the mixture was stirred at 25°C for 5 min using a magnetic stirrer. After stirring evenly, the mixture was placed in an oven and dried at 45°C for 5 h to obtain astaxanthin microcapsules. The astaxanthin microcapsules were ground and stored at room temperature in the dark.
[0109] Table 1 Amounts of astaxanthin, octenyl succinate starch, HPMC E5, Span 20 and anhydrous ethanol used in the preparation of astaxanthin microcapsules
[0110]
[0111] A PBS solution containing 1 wt % sodium dodecyl sulfate (SDS) and a pH of 7.4 was prepared, and the concentration of the PBS solution was 10 mM;
[0112] A certain amount of astaxanthin microcapsules were placed in 100 mL PBS solution, and the mixture was shaken at 100 rpm at 37°C. 3 mL of sample was taken at regular intervals and 3 mL of fresh PBS solution was added. The astaxanthin content was determined by high performance liquid chromatography.
[0113] The process of HPLC determination: After the sample is filtered through a syringe filter, it is analyzed on an Agilent C18 column with an injection volume of 20 μL. Finally, the cumulative dissolution of astaxanthin is calculated according to the following formula, and then the release curve is generated:
[0114] Astaxanthin cumulative dissolution (%) = (C n ×100+(C n-1 ×3+C n-2 ×3……+C2×3+C1×3)) / 200×100%;
[0115] Among them, C n is the concentration of astaxanthin in the samples taken at each time point.
[0116] The dissolution curve of astaxanthin microcapsules in PBS solution in Example 14 is as follows: Figure 7 As shown. Figure 7 It can be seen that when the mass ratio of octenyl succinate starch ester / HPMC E5 / Span 20 is 1:1:2 (Formula 4), the dissolution effect of the prepared astaxanthin microcapsules is the best, and this formula is preferred for preparing astaxanthin microcapsules with high bioavailability.
[0117] Using Discovery DSC TMThermal analysis was performed on the astaxanthin raw powder and the astaxanthin microcapsules obtained in Example 7. Specifically, a sample weighing 3 to 5 mg was placed in an aluminum crucible and pierced, and then heated from 30°C to 240°C at a rate of 10°C / min under a nitrogen flow to obtain a DSC spectrum.
[0118] like Figure 8 The DSC spectra of astaxanthin raw powder and astaxanthin microcapsules in Example 7 are shown in FIG. Figure 8 It can be seen that astaxanthin presents a sharp and single endothermic peak near 219°C, indicating that astaxanthin is in a crystalline state; and the melting point peaks of astaxanthin in astaxanthin microcapsules prepared with different mass ratios of octenyl succinate starch ester / HPMC E5 / Span 20 as excipients completely disappear, indicating that astaxanthin has completely transformed from a crystalline state to an amorphous state, a colloidal dispersion state or a molecular dispersion state.
[0119] It can be seen from the above embodiments that the present invention provides a highly bioavailable astaxanthin microcapsule and a preparation method thereof. Astaxanthin exists in an amorphous state, a colloidal dispersion state or a molecular dispersion state, and has a large dispersion degree, which increases the dissolution amount of astaxanthin in the medium, thereby increasing its bioavailability and ensuring the efficacy of astaxanthin; at the same time, the in vivo and in vitro recrystallization of astaxanthin is inhibited, thereby improving the stability of the microcapsule.
[0120] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for preparing astaxanthin microcapsules with high bioavailability, characterized in that: The following steps are involved: Astaxanthin, polysaccharide, cellulose derivative and surfactant are mixed to obtain a mixture, and astaxanthin microcapsules are obtained through a solvent method or a melting method.
2. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 1, characterized in that: The polysaccharide is sodium alginate, chitosan, beta-cyclodextrin, inulin, maltodextrin or octenyl succinate starch.
3. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 2, characterized in that: The cellulose derivative is hydroxypropyl methylcellulose, polyvinylpolypyrrolidone, copovidone or polyethylene glycol.
4. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 3, characterized in that: The surfactant is sorbitan fatty acid ester, sodium lauryl sulfate, vitamin E polyethylene glycol succinate, polyoxyethylene castor oil or polyoxyethylene (20) sorbitan monooleate.
5. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 4, characterized in that: The mass ratio of the astaxanthin, the polysaccharide, the cellulose derivative and the surfactant is 10.52:50-80:20-50:
100.
6. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 4 or 5, characterized in that: The process of the solvent method is: The mixture is mixed with an organic solvent, dispersed and dried to obtain astaxanthin microcapsules.
7. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 6, characterized in that: The mass ratio of the mixture to the volume ratio of the organic solvent is 1000-1055 mg: 10-15 mL; The organic solvent is ethanol, acetone or dichloromethane; The drying temperature is 40-60° C., and the drying time is 4-6 hours.
8. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 7, characterized in that: The process of the melting method is: The mixture is melted and cooled to obtain astaxanthin microcapsules.
9. The method for preparing astaxanthin microcapsules with high bioavailability according to claim 8, characterized in that: The melting temperature is >240° C., and the melting time is 15 to 20 minutes.
10. Astaxanthin microcapsules obtained by the method for preparing astaxanthin microcapsules with high bioavailability according to any one of claims 1 to 9.
